BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...Investments and OrbiMed Venture Partners, as well as new undisclosed strategic, corporate and financial investors. Danielle Golovin Novellus Ltd. Immune...
BioCentury | Sep 21, 2018
Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

...Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders...
...will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s...
...NovellusDx also will provide up to $2.3 million in a bridge loan to Cancer Genetics. NovellusDx...
BioCentury | Feb 9, 2015
Emerging Company Profile

Signal mapping

...cytoplasm to the nucleus to stimulate cell proliferation. "Passenger" mutations don't result in nuclear translocation. NovellusDx's...
...mutations in a patient's tumor result in translocation to distinguish the passenger and driver mutations. NovellusDx...
...Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. NovellusDx Ltd., Jerusalem, Israel Sidebars NovellusDx...
Items per page:
1 - 3 of 3
BioCentury | Sep 22, 2020
Finance

Sept. 21 Quick Takes: venture funding for Novellus, Immune Regulation, XWPharma and CoreMap

...Investments and OrbiMed Venture Partners, as well as new undisclosed strategic, corporate and financial investors. Danielle Golovin Novellus Ltd. Immune...
BioCentury | Sep 21, 2018
Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

...Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders...
...will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s...
...NovellusDx also will provide up to $2.3 million in a bridge loan to Cancer Genetics. NovellusDx...
BioCentury | Feb 9, 2015
Emerging Company Profile

Signal mapping

...cytoplasm to the nucleus to stimulate cell proliferation. "Passenger" mutations don't result in nuclear translocation. NovellusDx's...
...mutations in a patient's tumor result in translocation to distinguish the passenger and driver mutations. NovellusDx...
...Institutions Mentioned American Society of Clinical Oncology (ASCO), Alexandria, Va. NovellusDx Ltd., Jerusalem, Israel Sidebars NovellusDx...
Items per page:
1 - 3 of 3